ClinicaliQ Trial Snapshot
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) — Recruiting • Phase III • Oncology • NCT06943872.
- What is being tested: Sonrotoclax (a novel BCL2 inhibitor) combined with monoclonal antibodies (obinutuzumab or rituximab) versus the established standard treatment venetoclax plus rituximab in relapsed/refractory CLL/SLL, with progression-free survival as the primary endpoint.
- Patient eligibility overview: Adults with relapsed and/or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who have previously received at least one prior treatment regimen and meet standard haematological fitness criteria.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Eligibility Snapshot
- : * Confirmed diagnosis of CLL/SLL that meets the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria * Received one or more prior therapies for CLL/SLL. For each line of therapy, participants must have received at least 2 cycles of the therapy * Participants with prior BCL2i exposure are eligible if remission duration was ≥3 years with ≥2 years from last BCL2i intake * Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0, 1, or 2 * Adequate organ function
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.